The decision to accept a sibling with active hepatitis B virus (HBV) replication for hematopoietic stem cell (HSC) donation is controversial owing to the potential risk of viral transmission to the recipient and subsequent development of hepatitis B, which might be fatal. [1] [2] [3] Here, we report a successful strategy to prevent transmission from a viremic donor to an HBV-naive recipient.
A 23-year-old male with acute myeloblastic leukemia M1 was accepted for allogeneic transplantation after achieving complete remission. His only brother was human leukocyte antigen (HLA)-matched, but the donor was HBV-infected (serum positive for HB s Ag, anti-HB c , anti-HB e , HBV-DNA (11 400 copies/ml) and negative for HB e Ag) ( Table 1) . Serum aspartate aminotransferase and alanine aminotransferase (ALT) were normal; liver biopsy showed chronic inflammation and intracellular replication of the virus. No 10-antigen matched unrelated donor was identified, so the HBV( þ ) sibling was considered to be a better option compared to an alternative mismatched donor.
The HBV-infected donor was accepted with the following strategy to reduce the risk of virus passage: (1) the donor was treated with lamivudine (100 mg/day) to decrease serum virus to below the level of PCR detection (o300 copies/ml after 1 month). Lamivudine was continued until harvest of stem cells. (2) To reduce the volume of transplanted cells, granulocyte-colony stimulating factor mobilized peripheral blood mononuclear cells (G-PBMC) were chosen as a source of stem cells. Not more than 50 ml (one apheresis, Fenwall CS3000 Plus, Baxter, Warsaw, Poland) was planned to be infused, provided the product contained at least 4 Â 10 6 /kg of CD34 þ cells. (3) The recipient was immunized with recombinant hepatitis B vaccine. As the recipient's anti-HB s titer was very low, he was immunized passively with anti-HB s immunoglobulin 1 h before infusion of donor stem cells. (4) The recipient was treated with lamivudine from day À1 to day þ 30.
The conditioning regimen was oral busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). The patient subsequently received 50 ml of G-PBMC containing 6.3 Â 10 6 CD34 þ cells/kg with less than 300 copies/ml of HBV-DNA. Cyclosporine and a short course of methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. Between days þ 17 and 27, transient elevations of serum ALT (216 U/l) and total bilirubin (2.2 mg/dl) occurred. No symptoms of hepatic sinusoidal obstruction syndrome or GVHD were noted. Serum HBV-DNA was persistently negative after the transplant ( Table 1) . The patient became anti-HB c ( þ ) on day 30, but remained anti-HB e (À), anti-HB s (À) and HB s Ag(À). One year after transplantation, the patient responded to rHBV vaccine given at 1-month intervals. The anti-HBs titer after third dose increased to 370 mIU/ml and anti-HBc became negative. The patient remains in complete remission with no evidence of HBV infection or hepatic dysfunction now more than 2 years after transplantation.
It is difficult to determine which part of our strategy played the most important role in the prevention of HBV infection in our patient. However, the risk of passage of HBV by donor cells is mainly related to the presence of virus in the stem cell product, and not the mere presence of HBV infection in the donor. It has been long recognized that not all HB s Ag-positive donors transmit virus to their recipients, 2, 3 as not all are viremic. Given the lack of cellular immunity after a myeloablative regimen, it is difficult to know what level of HBV in the stem cell infusion can be given without resulting in infection. By inference from data on passage of hepatitis C virus from infected donors (all of whom transmit virus 4 ), zero HBV in the HBV-DNA, copies/ml 11 400 Not done o300 o300 o300 o300 0 Not done 
